Actinium Pharmaceuticals, Inc.

NYSEAM:ATNM Stock Report

Market Cap: US$58.6m

Actinium Pharmaceuticals Future Growth

Future criteria checks 2/6

Actinium Pharmaceuticals is forecast to grow earnings and revenue by 4.4% and 61.3% per annum respectively while EPS is expected to grow by 18.3% per annum.

Key information

4.4%

Earnings growth rate

18.3%

EPS growth rate

Biotechs earnings growth28.1%
Revenue growth rate61.3%
Future return on equityn/a
Analyst coverage

Low

Last updated03 Oct 2024

Recent future growth updates

Recent updates

Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Dec 28
Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Earnings and Revenue Growth Forecasts

NYSEAM:ATNM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20267-50-33-515
12/31/202515-35-38-545
12/31/2024N/A-42-46-415
6/30/20240-43-34-34N/A
3/31/20240-46-40-40N/A
12/31/20230-49-47-47N/A
9/30/2023N/A-50-48-48N/A
6/30/20230-46-42-42N/A
3/31/20230-39-1-1N/A
12/31/20221-3389N/A
9/30/20221-301111N/A
6/30/20221-271111N/A
3/31/20221-25-21-21N/A
12/31/20211-25-21-21N/A
9/30/20211-23-22-22N/A
6/30/20211-22-22-21N/A
3/31/20211-22-22-21N/A
12/31/2020N/A-22-22-22N/A
9/30/2020N/A-20-20-20N/A
6/30/2020N/A-21-21-21N/A
3/31/2020N/A-22-22-22N/A
12/31/2019N/A-22-22-21N/A
9/30/2019N/A-24-21-21N/A
6/30/2019N/A-23-22-22N/A
3/31/2019N/A-23-21-21N/A
12/31/2018N/A-24-21-21N/A
9/30/2018N/A-22-20-19N/A
6/30/2018N/A-23-19-19N/A
3/31/2018N/A-25N/A-22N/A
12/31/2017N/A-27N/A-22N/A
9/30/2017N/A-28N/A-23N/A
6/30/2017N/A-28N/A-22N/A
3/31/2017N/A-28N/A-21N/A
12/31/2016N/A-24N/A-21N/A
9/30/2016N/A-24N/A-21N/A
6/30/2016N/A-22N/A-18N/A
3/31/2016N/A-22N/A-17N/A
12/31/2015N/A-21N/A-19N/A
9/30/2015N/A-20N/A-20N/A
6/30/2015N/A-22N/A-20N/A
3/31/2015N/A-11N/A-18N/A
12/31/2014N/A-25N/A-14N/A
9/30/2014N/A-25N/A-11N/A
6/30/2014N/A-20N/A-8N/A
3/31/2014N/A-27N/A-6N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATNM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATNM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATNM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATNM's revenue (61.3% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: ATNM's revenue (61.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ATNM's Return on Equity is forecast to be high in 3 years time


Discover growth companies